Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2013

01-03-2013 | Original article

Up-regulation of Foxp3 participates in progression of cervical cancer

Authors: Chao Zeng, Yunhong Yao, Wei Jie, Miao Zhang, Xinrong Hu, Yi Zhao, Sen Wang, Jinbao Yin, Yulan Song

Published in: Cancer Immunology, Immunotherapy | Issue 3/2013

Login to get access

Abstract

Foxp3 was identified as a key protein in mediating inhibitory functions of regulatory T cell (Treg). Foxp3 was thought to express only in the T cell lineage until recently when some researches reported that Foxp3 was also expressed by cancer cells. In this study, we describe for the first time the expression of Foxp3 in cervical cancer. Progression from cervical intraepithelial neoplasia (CIN) to cervical cancer is a multistep process initiated by persistent infection with high-risk human papillomavirus (HPV). P16INK4a is a crucial marker of HPV integration into host cells. In the present study, expressions of Foxp3 and P16INK4a in CIN and cervical cancer were detected by immunohistochemistry. Our results found expression level of Foxp3 was increased during the progression of cervical neoplasia. Moreover, up-regulation of Foxp3 appeared to be correlated with the expression of P16INK4a. Examination of the role of Foxp3 in differentiation by double immunostaining for cytokeratin 10 (CK10) showed significant association between Foxp3 expression and differentiation (Foxp3 vs CK10). Furthermore, positive expression of Foxp3 was correlated with tumor size. These data suggest that Foxp3 may play an important role in differentiation and growth of cervical cancer cells. Our findings provide new insights regarding the role of Foxp3 in differentiation and its association with HPV infection during the development of cervical cancer.
Literature
1.
Parkin D, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24:S11–S25CrossRef
2.
Dehn D, Torkko KC, Shroyer KR (2007) Human Papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 111:1–14PubMedCrossRef
3.
Coffer PJ, Burgering BM (2004) Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4:889–899PubMedCrossRef
4.
Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22:329–341PubMedCrossRef
5.
Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061PubMedCrossRef
6.
Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMed
7.
Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423–5434PubMedCrossRef
8.
Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, Ohta M, Kitano S, Mori M (2008) Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 34:173–179PubMedCrossRef
9.
Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, Klöppel G, Kabelitz D, Kalthoff H (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67:8344–8350PubMedCrossRef
10.
Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746–1752PubMedCrossRef
11.
Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, Zheng P, Liu Y (2007) FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 117:3765–3773PubMed
12.
Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P (2009) Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 16:336–346PubMedCrossRef
13.
Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8:457–462PubMedCrossRef
14.
Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352PubMedCrossRef
15.
Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRef
16.
Zhang HY, Sun H (2010) Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett 28:791–797
17.
Cunha LL, Morari EC, Nonogaki S, Soares FA, Vassallo J, Ward LS (2012) Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics 67:483–488PubMedCrossRef
18.
Wang LH, Lin S, Wang JT (2010) Correlation between elevated FOXP3 expression and increase lymph node metastasis of gastric cancer. Chin Med J 123:3545–3549PubMed
19.
Niu J, Jiang C, Li C, Liu L, Li K, Jian Z, Gao T (2011) Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction. Cancer Immunol Immunother 60:1109–1118PubMedCrossRef
20.
Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H (2012) Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 75:95–101PubMedCrossRef
21.
Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Takeshita M, Suzumiya J, Utsunomiya A, Kikuchi M, Ohshima K (2008) The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol 21:617–625PubMedCrossRef
22.
Bolzer K, Käser T, Saalmüller A, Hammer SE (2009) Molecular characterisation of porcine Forkhead-box p3 (Foxp3). Vet Immunol Immunopathol 132:275–281PubMedCrossRef
23.
Boisvieux-Ulrich E, Le Pechon-Vallée C, Million K, Baeza-Squiban A, Houcine O, Guennou C, Reichert U, Marano F (2000) Differential effects of several retinoid receptor-selective ligands on squamous differentiation and apoptosis in airway epithelial cells. Cell Tissue Res 300:67–81PubMedCrossRef
24.
Wang WH, Jiang CL, Yan W, Zhang YH, Yang JT, Zhang C, Yan B, Zhang W, Han W, Wang JZ, Zhang YQ (2010) FOXP3 expression and clinical characteristics of hepatocellular carcinoma. World J Gastroenterol 16:5502–5509PubMedCrossRef
25.
Halloush RA, Akpolat I, Jim Zhai Q, Schwartz MR, Mody DR (2008) Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer 114:474–480PubMedCrossRef
26.
Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M (2002) p16 immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26:1389–1399PubMedCrossRef
Metadata
Title
Up-regulation of Foxp3 participates in progression of cervical cancer
Authors
Chao Zeng
Yunhong Yao
Wei Jie
Miao Zhang
Xinrong Hu
Yi Zhao
Sen Wang
Jinbao Yin
Yulan Song
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1348-8

Other articles of this Issue 3/2013

Cancer Immunology, Immunotherapy 3/2013 Go to the issue

Original article

MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients

Original Article

The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study

Original article

Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance

Original article

Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells

Original Article

Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response

Original article

Higher numbers of T-bet+ intratumoral lymphoid cells correlate with better survival in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits